Eli Lilly has announced its financial results for Q4 2024, highlighting strong revenue and profit growth fueled by key products.
Eli Lilly's Q4 2024 Financial Results
Eli Lilly reported $13.53 billion in revenue for Q4 2024, a 45% increase from the same period in 2023. This growth was driven primarily by a 48% increase in volume from products like Mounjaro and Zepbound, although lower prices caused a 4% decline. The company's net income doubled, with earnings per share reaching $4.88 on a reported basis, reflecting a 102% increase year-over-year.
Comparison with Market Expectations
While revenue of $13.53 billion fell short of the expected $13.78 billion, Eli Lilly exceeded expectations on non-GAAP earnings per share, reaching $5.32 compared to the expected $5.30. This suggests that Eli Lilly was able to manage costs effectively and optimize its product mix to deliver higher than expected earnings per share.
2025 Forecast
Eli Lilly has provided an optimistic revenue forecast for 2025 of $58 to $61 billion, indicating a potential growth of about 32%. The company plans to expand its production capacity and improve operational efficiency. It continues to invest in innovation, including clinical trials and portfolio development.
Eli Lilly demonstrates strong growth momentum, driven by successful products and strategic investments in capacity expansion and innovation. The company aims to continue improving its financial performance in the coming years.
